Additional subclones with loss of function (LOF) mutations in JAK proteins were also seen (Fig. 1), further implicating the role of IFN-γ and the adaptive immune response as major determinants of successful anti-tumour responses in KRAS-mutant malignancies [38]. This evidence concerns the gene KRAS and neoplasm.